D&D Pharmatech
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5th Floor I&c Building 24 Pangyo-ro 255 ...Phone Number
+82 3180197771Website
www.ddpharmatech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About D&D Pharmatech
D&D Pharmatech is a clinical-stage global biotech company that funds the development of medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company was founded in 2014 and has offices in Korea and US.Explore more
D&D Pharmatech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is D&D Pharmatech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on D&D Pharmatech recently announced quarterly report
D&D Pharmatech, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if D&D Pharmatech is spiking on competitors!
Product Launch: Get notified when D&D Pharmatech launches new products
Click to see if D&D Pharmatech had a recent Job posting/layoffs
Funding: Get notified immidiatlly once D&D Pharmatech has new funding data
Check if D&D Pharmatech has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at D&D Pharmatech
Recommended Actions
Find VP level buyers at D&D Pharmatech
Find 3 more new buyers
Company Profile Activity
Activity Insights
D&D Pharmatech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
D&D Pharmatech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about D&D Pharmatech.
D&D Pharmatech financials insights
Gather financial insights about D&D Pharmatech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series B
$137.1M
2021
Series C
$51M
2025
Debt
$10.8M
D&D Pharmatech Tech Stack
A closer look at the technologies used by D&D Pharmatech
Most Recent Scoops
Funding
Funding
Funding
New Hire
Executive Move
New Hire
Funding
Funding
Funding
Funding
D&D Pharmatech News & Media
LG AI Research Announces Collaboration with D&D Pharmatech to accelerate next-generation oral peptide drug discovery
- LG to secure leadership in the AI-bio market with its distinctive technological edge. SEOUL, South Korea, June 17, 2026 /PRNewswire/ -- LG AI Research announced today that it has signed a master agreement for a joint next-generation oral peptide drug development project with D&D...D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health
GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and metabolic diseases, today announced positive results from DD01-DN-02 study, an ongoing 48-week Phase 2 trial designed to evaluate the efficacy and safety of DD01 (a once-weekly dual GLP1/glucagon receptor agonist) in 67 overweight/obese subjects with MASH. DD01 treatment was initiated with twoD&D Pharmatech Announces Completion of Patient Enrollment for a 48-Week Phase 2 Trial Evaluating the Effectiveness of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist, in the Treatment of MASH
GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company focused on the development of disease-modifying drugs, today, announced that patient enrollment has been completed for DD01-DN-2, an ongoing Phase 2 trial designed to evaluate the efficacy and safety of DD01 in overweight/obese subjects with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH). DD01 is a liver-targeted, loNeuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04
KNOXVILLE, Tenn.--(BUSINESS WIRE)--On January 16, 2025, Neuraly Inc. (Neuraly), a wholly owned subsidiary of D&D Pharmatech Inc., and Enigma Biomedical USA, Inc. (Enigma) announced the signing of a research license and commercialization option agreement for PMI04, a PET (Positron Emission Tomography) imaging biomarker of neuroinflammation developed by Neuraly. Under the agreement, Enigma acquires an exclusive research license for PMI04, as well as the option to negotiate commercialization r
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding D&D Pharmatech
Sign Up For FreeTo access detailed company insights
D&D Pharmatech is a clinical-stage global biotech company that funds the development of medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company was founded in 2014 and has offices in Korea and US.... Read More
